Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly M3PQVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPpTWM2OD1yLkGy5qCKyrIkgJmwMlAyKM7:TR?= NYTuNlhyOjV7NkCyPFI>
KellyCis83 MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi3Z2JbUUN3ME2wMlE36oDLwsJihKkxNjB{IN88US=> M{W4NFI2QTZyMkiy
SK-N-AS NI\le4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr0NnBKSzVyPUCuNlTjiIoEsfMAjVAvODNizszN NWnibZV3OjV7NkCyPFI>
SK-N-ASCis24 M3\Gfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjJTmxKSzVyPUCuOVfjiIoEsfMAjVAvOTFizszN MVeyOVk3ODJ6Mh?=
U87 NYr1fHdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXHNE02OCEQvF2= MVe0PEBp Mmj3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfobYNpKGOjbjDi[UBmdmijbnPl[EBjgSC|aXzpZolvcW5? Mni3NlU4PTB{N{O=
HCT116 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLQT3cxNjVvMj61JO69VQ>? MnrnOFjDqGkEoB?= NU\HSo5iUUN3ME2xMlc{yqEEsdMgNE4zOcLizszN NH[zWXMzPTd2Nke2Ny=>
HT-29 M4XuXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon3NE42NTJwNTFOwG0> MV:0POKhcMLi NUjyNFQzUUN3ME23MlLDqMLzwrCxMlA1yqEQvF2= NXLqb3hLOjV5NE[3OlM>
Caco2 M2XLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOwMlUuOi53IN88US=> NHfUZoo1QMLiaNMg MXXJR|UxRTdwMkdCpOKyyqBzLk[4xsDPxE1? M2rGTFI2PzR4N{[z
COLO 205 NWHNbYk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPwdoZwOC53LUKuOUDPxE1? M1frRlQ5yqCqwrC= M1zJTWlEPTB;MT62NeKhyrIEoECuNFLDqM7:TR?= Mkf3NlU4PDZ5NkO=
SW480 NIfJXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlK4NE42NTJwNTFOwG0> NEXzS441QMLiaNMg M1THb2lEPTB;ND65NuKhyrIEoECuN|PDqM7:TR?= MkKyNlU4PDZ5NkO=
HEK293T NW\FeFYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEKy[JkyNTVizszN MVi0POKhcMLi M{X2VWlEPTB;Mj60NuKhyrIEoECuNFXDqM7:TR?= NVjq[pRzOjV5NE[3OlM>
Hep3B  M{Xy[WZ2dmO2aX;uJGF{e2G7 NVvYTVh4OTBizszN NXLRWIVMPDkEoHlCpC=> MmLCdoVlfWOnczD0bIUh\W6qYX7jbY5oKGWoZnXjeEBw\iCETWCtOi=> M3zoOlI2PjN|NU[0
Hep3B  Ml3sSpVv[3Srb36gRZN{[Xl? M2LGWVAvOS1zMDFOwG0> MYKyOEBp MVzzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJIhmeGOrZHnuJI1TVkF? NIHNXpgzPTZ|M{W2OC=>
HEK293 NFrlfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm1TWM2OD15LkG0xsDDucLiMD6zOuKh|ryP MlrTNlU3ODNzMkK=
DU145 Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TQTWlEPTB;Mj6yPOKhyrIEoECuNFTDqM7:TR?= NWTCVZR4OjV4MEOxNlI>
HCT15 NHHiSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwOEJCpOKyyqByLkCxxsDPxE1? M4rYNVI2PjB|MUKy
T47D MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TIe2lEPTB;Mz6xPOKhyrIEoECuNVHDqM7:TR?= Mof4NlU3ODNzMkK=
SMMC-7721 MmfFSpVv[3Srb36gRZN{[Xl? NU\UZWlrPDBizszN NXvPZVVzPDhiaB?= MX\EUXNQ NXTQ[pFzcW6mdXPld{DPu0h{QWig[o9kcSCob4LtZZRqd25? MmLVNlU2PDR|NkG=
MDA-MB-231 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzLdFc4OsLiaB?= M4T3V2lEPTB;MkGuNuKhyrIEoESuNuKh|ryP NXLJdlJiOjV2OE[yNVk>
MCF-7 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUm3NuKhcA>? M2ruXGlEPTB;MUCuPeKhyrIEoEKuNeKh|ryP M1zBfFI2PDh4MkG5
Jurkat MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnVUZM4OsLiaB?= NUHtNnB4UUN3ME2xMlLDqMLzwrCxMlXDqM7:TR?= NVT6SoJJOjV2OE[yNVk>
HeLa NXrLeXBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXi3NuKhcA>? MV;JR|UxRTNwOdMgxtHDqDJwM9Mg{txO NH32UWkzPTR6NkKxPS=>
MCF7  MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHN[mw2NTFyMDFOwG0> M1fzd|ch\A>? NY[zN3FJcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2SwPFI2PDd{NkG5
K562 MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7YWpo4OsLiaB?= M2TZSGlEPTB;MD6yPeKh|ryP NY\WXpJrOjV{OEK2OVM>
K/VP.5 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LsUFczyqCq Mo[0TWM2OD12LkpCpO69VQ>? Ml[yNlUzQDJ4NUO=
SH-EP  NULQXIo{TnWwY4Tpc44hSXO|YYm= MX6yNOKh|rypL33s Ml3WNlTDqGh? NVHWVXdYcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGWwZH;n[Y5wfXNiRFXQVC=> M4XCbVI2OjZzOUix
SCC25 NF;vV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m5SFI1yqCq NE\qfYFKSzVyPUSzMlPDqMLzwrCxMlEzyqEQvF2= Ml64NlUzOjB5Mkm=
CAL27 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnIWI5KOjUEoHi= MYfJR|UxRTV{LkJCpOKyyqBzLkC5xsDPxE1? NIi0T5ozPTJ{MEeyPS=>
FaDu NYnzTJViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu4TYczPMLiaB?= NF[1d3lKSzVyPUK1Mlg6yqEEsdMgNU4yO8LizszN Mny1NlUzOjB5Mkm=
SCC25 NVHsNno6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\kUoQ1QMLiaB?= NYnCe2xWUUN3ME2yNE45PsLiwsJCpFEvODgEoN88US=> M1vPblI2OjJyN{K5
CAL27 M1Xrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XsSVQ5yqCq MWTJR|UxRTF6LkK0xsDDucLiMT6xOeKh|ryP MofLNlUzOjB5Mkm=
FaDu Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfQfZVTPDkEoHi= M2jEOWlEPTB;Nj60N:KhyrIEoEGuNVPDqM7:TR?= NWm0[I5yOjV{MkC3Nlk>
SCC25 NFP4bHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[3NuKhcA>? NE\DbXdKSzVyPUiuOFHDqMLzwrCxMlEyyqEQvF2= Mn7INlUzOjB5Mkm=
CAL27 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUS3NuKhcA>? Ml:4TWM2OD12LkK3xsDDucLiMT6xOOKh|ryP M4HJPVI2OjJyN{K5
FaDu NWPVcFQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoKyO|LDqGh? NIS3VINKSzVyPUWuNFLDqMLzwrCxMlE2yqEQvF2= MmPlNlUzOjB5Mkm=
MCF-7 NHe1S5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjSbotxPDkEoHlCpC=> NEHGN49FVVOR NF\JOolKSzVyPUeuNuKhyrIEoECuPOKh|ryP NUTESXdmOjV{MU[zO|g>
T-47D NFLmdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\5cGY1QMLiaNMg NF6zeHNFVVOR MV3JR|UxRTdwN9MgxtHDqDBwN9Mg{txO MVKyOVIyPjN5OB?=
MDA-MB-231 M4faN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TI[VQ5yqCqwrC= MnS2SG1UVw>? MlGzTWM2OD1zMj64xsDDucLiMT6wxsDPxE1? M{XRWVI2OjF4M{e4
DU145 MljwRZBweHSxc3nzJGF{e2G7 NHezU4syOC1zMECg{txO NHvBR2Q5KGh? NED2eI5FVVOR NHXDRlNqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= NXzkRZV1OjVzNEm2PFE>
DU145 stem-like NVXzbGtQSXCxcITvd4l{KEG|c3H5 NGTDR3IyOC1zMECg{txO MnnTPEBp NY[0TWFUTE2VTx?= M3mwb4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NIm5Z3gzPTF2OU[4NS=>
DU145 NGPmbXVHfW6ldHnvckBCe3OjeR?= Mnj2NVAuOTByIN88US=> MnvwNkBp NXT6e4d1TE2VTx?= NUK3c21PcW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHrmXmgzPTF2OU[4NS=>
DU145 stem-like NHTRUHFHfW6ldHnvckBCe3OjeR?= MWixNE0yODBizszN NUPEb5pFOiCq M1XFeWROW09? M{GyV4lv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MXiyOVE1QTZ6MR?=
UW228-3 NVm3UHkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfLNE4xOS1|MECg{txO MoTPOFghcA>? MmXPSG1UVw>? M3uxV2lEPTB;MD65PeKh|ryP NY\iZpM3OjVzMUmxPFU>
NSCs NXT1W2plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDEfGQxNjBzLUOwNEDPxE1? M{P6VFQ5KGh? MnTjSG1UVw>? NY\1enVYUUN3ME2wMlMuO8LizszN NIrpR3EzPTFzOUG4OS=>
MKL-1  NH:yeXJHfW6ldHnvckBCe3OjeR?= MXuxNE0yODByIH7N NXvJTWZ5PCCm NVzwcFNqcW6mdXPld{B1cGViaX7keYN1cW:wIH;mJG1JSy2LIHX4dJJme3Orb36= MnjuNlUyOTZ5NUS=
MCF7 EV NFr1[m1HfW6ldHnvckBCe3OjeR?= MUSxNE0yODBizszN M3O4fFLjiImq MW\pcoR2[2W|IIDyc4R2[3Srb36gc4bDqM7|SELBXC=> MYCyOVA5QDJyMx?=
MCF 7BMI1 NIPmUGVHfW6ldHnvckBCe3OjeR?= MXSxNE0yODBizszN MmXsNwKBkWh? NFywRWNqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? MWqyOVA5QDJyMx?=
MCF7 EV MX7GeY5kfGmxbjDBd5NigQ>? MkPCNVAuOTByIN88US=> NWT4OHl{OuLCiXi= NXzSemVMTVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v NUnT[41MOjVyOEiyNFM>
MCF7 BMI1 NXXCZWxiTnWwY4Tpc44hSXO|YYm= Ml23NVAuOTByIN88US=> MkTQNwKBkWh? NGfGOYlGXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> M1jTOVI2ODh6MkCz
HepG2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHYSG1UV8Li M12xZWlEPTB;M{CuNVbDqMLzwrCwMlUxyqEQvF2= M13zUVI2ODd6M{Gx
MOLT-3 MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvEUXNQyqB? Ml7JTWM2OD1yLkC1NeKhyrIEoECuNFAzyqEQvF2= NF3hU40zPTB5OEOxNS=>
HT1080 NVH2NpViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz1c40yNTFyMDFOwG0> M2fBZlQwOjRxNEigbC=> M1zUcGROW00EoB?= NEj6dXBqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= NWTQcoNPOjVyN{iwOlQ>
HT1080 MnztSpVv[3Srb36gRZN{[Xl? MUCwMlAxODFvMUCwJO69VQ>? NVTRdnZnOS1{NDDo NHG4b2VFVVORwrC= NWD3VnlIcW6mdXPld{BxNXB3Mzjz[ZIyPSliaX6gZo91cCC2aX3lMUBidmRiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy M2Drc|I2ODd6ME[0
HT1080 M3yzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jBNFAvODByMT2xNFAh|ryP MlnKNlQhcA>? NEXoUHlFVVORwrC= MULjZZV{\XNiYX6gbY5kemWjc3WgbY4hfGinIH71cYJmeiCxZjDj[YxteyCrbjDHNk9ONCC5aHns[UBl\WO{ZXHzbY5oKFNiYX7kJGcyKHCqYYPlJINmdGy| MUCyOVA4QDB4NB?=
HD-MY-Z MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;wNlQwPDhxN{KgbC=> MXjJR|Ux97zgMUCwJO69VQ>? NUL4VI9ROjVyNEiyN|Y>
DOHH-2 M4jIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLVSHAzPCCq M3OxUWlEPTExvK6xNFAh|ryP NGe0O2QzPTB2OEKzOi=>
DOHH-2 MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzLXpM1QCCq NWnwWm9wUUN3ME2xPU46yqEQvF2= NH36WIEzPTB2OEKzOi=>
DOHH-2 NVrFU2pJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\YO|IhcA>? MkX6TWM2OD13wrFOwG0> NXj0WoI{OjVyNEiyN|Y>
REH M3SxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSyOEBp M1O4Z2lEPTB;MD6wNlfDqM7:TR?= NGDHSHYzPTB2OEKzOi=>
REH M2CzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnhOXc1QCCq NYe4ZVd{UUN3ME2wMlAyPMLizszN MWiyOVA1QDJ|Nh?=
REH M3fLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP5O|IhcA>? MUHJR|UxRTBwMEG1xsDPxE1? M1zwUVI2ODR6MkO2
HH MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvyNFEzPCCq MlrxTWM2OD1zMESuO:Kh|ryP MnvqNlUxPDh{M{[=
HH MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjxSXo3PDhiaB?= NFzRSWVKSzVyPUS4MlbDqM7:TR?= M1f3OFI2ODR6MkO2
HH MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHnO|IhcA>? M1LKRmlEPTB;MUSuO:Kh|ryP MlzXNlUxPDh{M{[=
HuT-78 MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLOZXJ5OjRiaB?= MlHpTWM2OD17LkRCpO69VQ>? NV74fVE3OjVyNEiyN|Y>
HuT-78 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;TVnhMPDhiaB?= MXLJR|UxRTRwM9Mg{txO MYiyOVA1QDJ|Nh?=
HuT-78 M1XYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHFUpV4PzJiaB?= MWfJR|UxRTRwMtMg{txO NVTv[5NJOjVyNEiyN|Y>
OPM-2 NF[1WoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjD[mozPCCq NIW4S4dKSzVyPUK0MlHDqM7:TR?= M4jud|I2ODR6MkO2
OPM-2 M3TXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L5WlQ5KGh? MXrJR|UxRTUEoN88US=> M1rrTFI2ODR6MkO2
OPM-2 M4\PU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYm3NkBp Mk\iTWM2OD1zLkRCpO69VQ>? M13ZcVI2ODR6MkO2
RPMI-8226 NXTydJhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:1VJUzPCCq MY\JR|UxRTFyNj62xsDPxE1? MmDxNlUxPDh{M{[=
RPMI-8226 M3\sOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLFWVNuPDhiaB?= M{HrNWlEPTB;OUGuNeKh|ryP M3LmT|I2ODR6MkO2
RPMI-8226 MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETwXlc4OiCq MoHYTWM2OD1zND65xsDPxE1? M3TJSVI2ODR6MkO2
U-266 M2nKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSyOEBp MX7JR|UxRTh4LkNCpO69VQ>? NVjVSYpLOjVyNEiyN|Y>
U-266 M1KwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYG0PEBp NH24R2FKSzVyPU[4MlTDqM7:TR?= MXqyOVA1QDJ|Nh?=
U-266 NX7LWZFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3iV4REPzJiaB?= NFrIVGtKSzVyPUK3MlTDqM7:TR?= NWn4c3VmOjVyNEiyN|Y>
Kelly NV7lOoNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\JS2wxNTFyIN88US=> NIfTOYw4OsLiaB?= M{fpUmlEPTB;MT61NVjDqM7:TR?= MlfGNlUxODh7MEC=
SH-SY5Y  MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnNNHFZOC1zMDFOwG0> MVW3NuKhcA>? Mlj3TWM2OD1yLke1OOKh|ryPwrC= MXuyOVAxQDlyMB?=
SK-N-AS MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUGwMVExKM7:TR?= Ml7nO|LDqGh? M1HKW2lEPTB;MT63NVLDqM7:TdMg NHn0[4kzPTByOEmwNC=>
SK-N-DZ MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13T[FAuOTBizszN MVO3NuKhcA>? M{K5dmlEPTB;NT60PFXDqM7:TR?= NFnFWFAzPTByOEmwNC=>
HepG2 NGnHZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDXXms1QMLiaB?= NGO2bYhFVVORwrC= M3;TemlEPTB;MUOuOlXDqMLzwrCwMlkzyqEQvF2= M{nuNlI1QTl4MUO2
A549 NU\LNVY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHy0XZo1QMLiaB?= NVnFcGZlTE2VT9Mg MkTZTWM2OD1{NEGuPeKhyrIEoEOxMlI{yqEQvF2= M{DMNFI1QTl4MUO2
MCF7 NXTFToVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[0POKhcA>? MmLMSG1UV8Li NHT0PWdKSzVyPUixMlA6yqEEsdMgNVQvOjIEoN88US=> NIjK[mgzPDl7NkGzOi=>
HL-60  MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYC3NuKhcA>? NWP0TJN1UUN3ME2wMlEz6oDHzszN NILqcXMzPDl7M{CxOC=>
HL-60[R] M13Mfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUi3NuKhcA>? M3jDPWlEPTB;Mz6xNwKBjc7:TR?= NH3Tb5AzPDl7M{CxOC=>
MIAPACA MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL6bWJ4T0l3ME2xMlMhyrFiMD6wN{DPxE1? NHj4OY4zPDl3M{iyNS=>
MCF-7 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPHTVUxRTBwMkWgxtEhOC5zIN88US=> M{HI[FI1QTV|OEKx
HeLa M4i4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULHTVUxRTBwNkSgxtEhOC52IN88US=> NHHY[mozPDl3M{iyNS=>
MO59K  M3LuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vpU|ch\A>? MoLQTWM2OD1yLkG35qCG|ryP NX\Fd4doOjR7NUO1OlE>
MO59J NYn2VZZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvuOWhSPyCm NFroephKSzVyPUCuNgKBjc7:TR?= NXLkfY5xOjR7NUO1OlE>
ME 180 NV\nSVhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHyOFjDqGkEoB?= NGjuSpFKSzVyPUiuPeKhyrIEoECuN-KBjc7:TR?= NH[0[HMzPDl3M{CyOy=>
MCF-7 NUCxTYJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHSOZp3PDkEoHlCpC=> M2DMXWlEPTB;MkOuPUDDuSByLkRihKXPxE1? MmDvNlQ6PTNyMke=
HeLa Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX34d4RRPDkEoHlCpC=> M3TNRmlEPTB;ND63NUDDuSBzLkVihKXPxE1? NWG2Xm5OOjR7NUOwNlc>
MDA-MB-453 M1\p[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLMOFjDqGkEoB?= NGjKcVFKSzVyPUGyMlUhyrFiMD64OgKBjc7:TR?= M3PPWVI1QTV|MEK3
MDA-MB-231 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLJVohtPDkEoHlCpC=> Ml\2TWM2OD1{ND6yNkDDuSB{Lkm05qCG|ryP NFrjVIszPDl3M{CyOy=>
PC-3 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnS3OFjDqGkEoB?= M37wU2lEPTB;MUSuOEDDuSB|LkKz5qCG|ryP M17ZdFI1QTV|MEK3
HT-29 NIDTRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\hTVQ5yqCqwrC= NWfMOGt7UUN3ME2yNU41PSEEsTCzMlg46oDHzszN MYOyOFk2OzB{Nx?=
BGC-823 NWfWVIh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPoOFjDqGkEoB?= NVTBdJlqUUN3ME20N{44PCEEsTC1MlE{6oDHzszN NYTjdXMxOjR5OUO4O|c>
HeLa M4\jS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrGOFjDqGkEoB?= MVrJR|UxRTJyOT65NEDDuSBzMz60NkDjiIYQvF2= MoTNNlQ4QTN6N{e=
A549 MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHJOWxqPDkEoHlCpC=> MlHmTWM2OD1zM{muOVQhyrFiNz6wOgKBjc7:TR?= M4noV|I1Pzl|OEe3
HK-2 NHrLPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[0POKhcMLi NXzuN2V2UUN3ME25MlE4KMLzIEGuOVjjiIYQvF2= NGH6UYczPDd7M{i3Oy=>

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+30% PEG 300+H2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID